Asset profile
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the tre…
Newest first.
Palatin Advances PL2000 MC4R Agonist to Phase 1 in H1 2027
Other drugs and candidates from the same company tracked in this sector.